Skip to main content
Top
Published in: Journal of Bioethical Inquiry 1/2018

01-03-2018 | Original Research

An Exploration of the Protective Effects of Investigators’ Ethical Awareness upon Subjects of Drug Clinical Trials in China

Authors: L. Zhang, X. X. Huang, H. F. Chen

Published in: Journal of Bioethical Inquiry | Issue 1/2018

Login to get access

Abstract

Up till now, China has not enacted any legal mechanisms governing certification or supervision for ethics committees. This article analyses deficiencies in the protection of subjects in clinical drug trials under China’s current laws and regulations; it emphasizes that investigators, as practitioners who have direct contact with subjects, play significant roles in protecting and safeguarding subjects’ rights and interests. The paper compares the status quo in China in this area to that of other countries and discusses ways China might enhance the protection of rights and interests of trial subjects, such as enhancing the ethical awareness of investigators through training, improving laws and regulations, and strengthening the communication between investigators and ethics committees.
Literature
go back to reference Adedeji, W.A., W.A. Ibraheem, and F.A. Fehintola. 2013. Attitude and practice of doctors toward adverse drug reactions (ADRs) reporting in a Nigerian tertiary health facility. Annals of Ibadan Postgraduate Medicine 11(2): 77–80.PubMedPubMedCentral Adedeji, W.A., W.A. Ibraheem, and F.A. Fehintola. 2013. Attitude and practice of doctors toward adverse drug reactions (ADRs) reporting in a Nigerian tertiary health facility. Annals of Ibadan Postgraduate Medicine 11(2): 77–80.PubMedPubMedCentral
go back to reference Afifi, S., N. Maharloui, P. Peymani, et al. 2014. Adverse drug reactions reporting: Pharmacists’ knowledge, attitude and practice in Shiraz, Iran. International Journal of Risk & Safety in Medicine 26(3): 139–145. Afifi, S., N. Maharloui, P. Peymani, et al. 2014. Adverse drug reactions reporting: Pharmacists’ knowledge, attitude and practice in Shiraz, Iran. International Journal of Risk & Safety in Medicine 26(3): 139–145.
go back to reference Ajzen, I. 1991. The theory of planned behavior. Organizational Behavior & Human Decision Processes 50(2): 179–211.CrossRef Ajzen, I. 1991. The theory of planned behavior. Organizational Behavior & Human Decision Processes 50(2): 179–211.CrossRef
go back to reference Avilds, M.R. 2014. Compensation of research-related injuries in the European Union. European Journal of Health Law 21(5): 473–487.CrossRefPubMed Avilds, M.R. 2014. Compensation of research-related injuries in the European Union. European Journal of Health Law 21(5): 473–487.CrossRefPubMed
go back to reference Beck, N. 2015. What a surgeon needs to know of the work of a medical ethics committee/institutional review board. Zentralblatt Für Chirurgie 140(1): 63–66.PubMed Beck, N. 2015. What a surgeon needs to know of the work of a medical ethics committee/institutional review board. Zentralblatt Für Chirurgie 140(1): 63–66.PubMed
go back to reference Brinker, A.D., J. Lyndly, J. Tonning, et al. 2013. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA adverse event reporting system (FAERS) database. Drug Safety 36(12): 1169–1178.CrossRefPubMed Brinker, A.D., J. Lyndly, J. Tonning, et al. 2013. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA adverse event reporting system (FAERS) database. Drug Safety 36(12): 1169–1178.CrossRefPubMed
go back to reference Chieko, K., K. Hideo, O. Shunsuke, et al. 2014. High rate of awarding compensation for claims of injuries related to clinical trials by pharmaceutical companies in Japan: A questionnaire survey. PloS ONE 9(1): e84998.CrossRef Chieko, K., K. Hideo, O. Shunsuke, et al. 2014. High rate of awarding compensation for claims of injuries related to clinical trials by pharmaceutical companies in Japan: A questionnaire survey. PloS ONE 9(1): e84998.CrossRef
go back to reference Cong, Y.L. 2010. Comparative study on the protection of Chinese and American subjects in clinical trial—From the perspective of institutional review board. Journal of Peking University (Health Sciences) 42(6): 625–628. Cong, Y.L. 2010. Comparative study on the protection of Chinese and American subjects in clinical trial—From the perspective of institutional review board. Journal of Peking University (Health Sciences) 42(6): 625–628.
go back to reference Frye, R.L., R.D. Simari, B.J. Gersh, et al. 2009. Ethical issues in cardiovascular research involving humans. Circulation 120(21): 2113–2121.CrossRefPubMed Frye, R.L., R.D. Simari, B.J. Gersh, et al. 2009. Ethical issues in cardiovascular research involving humans. Circulation 120(21): 2113–2121.CrossRefPubMed
go back to reference Garattini, S., and V. Bertele. 2009. Ethics in Clinical Research. Journal of Hepatology 51(4): 792–797.CrossRefPubMed Garattini, S., and V. Bertele. 2009. Ethics in Clinical Research. Journal of Hepatology 51(4): 792–797.CrossRefPubMed
go back to reference International Committee of Medical Journal Editors. 1997. Uniform requirements for manuscripts submitted to biomedical journals. New England Journal of Medicine 1997(336): 309–316. International Committee of Medical Journal Editors. 1997. Uniform requirements for manuscripts submitted to biomedical journals. New England Journal of Medicine 1997(336): 309–316.
go back to reference Jos, D. 2004. Clinical trial insurance in a comparative law perspective. Medicine & Law 23(2): 211–218. Jos, D. 2004. Clinical trial insurance in a comparative law perspective. Medicine & Law 23(2): 211–218.
go back to reference Kircher, S.M., A.B. Benson, F. Matthew, et al. 2012. Effect of the Accountable Care Act of 2010 on clinical trial insurance coverage. Journal of Clinical Oncology 30(5): 548–553.CrossRefPubMed Kircher, S.M., A.B. Benson, F. Matthew, et al. 2012. Effect of the Accountable Care Act of 2010 on clinical trial insurance coverage. Journal of Clinical Oncology 30(5): 548–553.CrossRefPubMed
go back to reference Lei, X., W.K. Zheng, H. Wang, et al. 2014. The reasons of poor recording of adverse events in clinical trials and methods for improvement. Chinese Journal of New Drugs 23(11): 1260–1263. Lei, X., W.K. Zheng, H. Wang, et al. 2014. The reasons of poor recording of adverse events in clinical trials and methods for improvement. Chinese Journal of New Drugs 23(11): 1260–1263.
go back to reference Le Journal Médical Libanais. 1994. Recommendations guiding physicians in biomedical research involving human subjects. World Medical Association Declaration of Helsinki. 42(2): 2191–2194. Le Journal Médical Libanais. 1994. Recommendations guiding physicians in biomedical research involving human subjects. World Medical Association Declaration of Helsinki. 42(2): 2191–2194.
go back to reference Levine, R.J. 2001. Lecture on history of human research subject use in the U.S. Medicine & Philosophy 12. Levine, R.J. 2001. Lecture on history of human research subject use in the U.S. Medicine & Philosophy 12.
go back to reference Li, X., X.X. Li, Z.J. Liu, et al. 2010. Analysis of safety reporting in clinical trials on herbal medicine published in Chinese journals. Chinese Journal of Pharmacovigilance 7(1): 20–24. Li, X., X.X. Li, Z.J. Liu, et al. 2010. Analysis of safety reporting in clinical trials on herbal medicine published in Chinese journals. Chinese Journal of Pharmacovigilance 7(1): 20–24.
go back to reference Li, Y.X. and J. Li. 2015. On the significance of communication in the ethical review management of drug clinical trials. Medicine and Philosophy 36 (2A): 33–36. Li, Y.X. and J. Li. 2015. On the significance of communication in the ethical review management of drug clinical trials. Medicine and Philosophy 36 (2A): 33–36.
go back to reference Liang, Y.H. 2012. Efficacy observation of treating proteinuria with nephritis rehabilitation film combined with Campbell water capsules. Clinical Journal of Chinese Medicine 4(2): 41–42. Liang, Y.H. 2012. Efficacy observation of treating proteinuria with nephritis rehabilitation film combined with Campbell water capsules. Clinical Journal of Chinese Medicine 4(2): 41–42.
go back to reference Morris, N., and B. Balmer. 2006. Volunteer human subjects understandings of their participation in a biomedical research experiment. Social Science & Medicine 62(4): 998–1008.CrossRef Morris, N., and B. Balmer. 2006. Volunteer human subjects understandings of their participation in a biomedical research experiment. Social Science & Medicine 62(4): 998–1008.CrossRef
go back to reference Nahler, M.P.G. 2009. Clinical trial compensation guidelines. Vienna: Springer.CrossRef Nahler, M.P.G. 2009. Clinical trial compensation guidelines. Vienna: Springer.CrossRef
go back to reference Nakamura, T., N. Ichikawa, K. Egashira, et al. 2008. Comparison of compensation-related documents provided by clinical trial sponsors and medical institutions. Japanese Journal of Pharmaceutical Health Care & Sciences 34(5): 461–466. Nakamura, T., N. Ichikawa, K. Egashira, et al. 2008. Comparison of compensation-related documents provided by clinical trial sponsors and medical institutions. Japanese Journal of Pharmaceutical Health Care & Sciences 34(5): 461–466.
go back to reference Paasche-Orlow, M.K., H.A. Taylor, and F.L. Brancati 2003. readability standards for informed-consent forms as compared with actual readability. New England Journal of Medicine 348(8): 721–726.CrossRefPubMed Paasche-Orlow, M.K., H.A. Taylor, and F.L. Brancati 2003. readability standards for informed-consent forms as compared with actual readability. New England Journal of Medicine 348(8): 721–726.CrossRefPubMed
go back to reference Rose, K., and H. Kummer. 2015. A new ethical challenge for institutional review boards (IRBs)/ethics committees (ECs) in the assessment of pediatric clinical trials. Children 2(2): 198–210.CrossRefPubMedPubMedCentral Rose, K., and H. Kummer. 2015. A new ethical challenge for institutional review boards (IRBs)/ethics committees (ECs) in the assessment of pediatric clinical trials. Children 2(2): 198–210.CrossRefPubMedPubMedCentral
go back to reference Sengupta, A. 2009. Fatal trials: Clinical trials are killing people. Indian Journal of Medical Ethics 6(3): 118–119.PubMed Sengupta, A. 2009. Fatal trials: Clinical trials are killing people. Indian Journal of Medical Ethics 6(3): 118–119.PubMed
go back to reference Shen, Y.H., Z.F Zhang. and Z. Q. Li 2011. Current status and regulatory measures for the ethics committee of drug clinical trial institutions in China. Chinese Journal of Clinical Pharmacology 27(8): 654–656. Shen, Y.H., Z.F Zhang. and Z. Q. Li 2011. Current status and regulatory measures for the ethics committee of drug clinical trial institutions in China. Chinese Journal of Clinical Pharmacology 27(8): 654–656.
go back to reference Speers, M. 2012. Accreditation of human research protection programs. In Principles and Practice of Clinical Research, edited by J. Gallin and F. Ognibene, 161–170. Washington D.C.: Association for the Accreditation of Human Research Protection Programs, Inc. Speers, M. 2012. Accreditation of human research protection programs. In Principles and Practice of Clinical Research, edited by J. Gallin and F. Ognibene, 161–170. Washington D.C.: Association for the Accreditation of Human Research Protection Programs, Inc.
go back to reference Veronica, Y., and R. Drummond. 2002. Reporting of informed consent and ethics committee approval in clinical trials. JAMA 287(21): 2835–2838.CrossRef Veronica, Y., and R. Drummond. 2002. Reporting of informed consent and ethics committee approval in clinical trials. JAMA 287(21): 2835–2838.CrossRef
go back to reference Wei, Y., M.Z Liang., S.Z. Wu, et al. 2013. The participating willingness of subjects and ethic consideration in clinical study. Chinese Journal of Clinical Research 10(2): 26–29. Wei, Y., M.Z Liang., S.Z. Wu, et al. 2013. The participating willingness of subjects and ethic consideration in clinical study. Chinese Journal of Clinical Research 10(2): 26–29.
go back to reference Williams, C.J., and M. Zwitter 1994. Informed consent in European multicentre randomised clinical trials–Are patients really informed? European Journal of Cancer 30(7): 907–910.CrossRef Williams, C.J., and M. Zwitter 1994. Informed consent in European multicentre randomised clinical trials–Are patients really informed? European Journal of Cancer 30(7): 907–910.CrossRef
go back to reference Yao, Z.P., X. Jin, J.W. Wang, et al. 2012. Ethic problems and strategies for drug clinical trials in China. China Pharmacy 23(21): 1931–1933. Yao, Z.P., X. Jin, J.W. Wang, et al. 2012. Ethic problems and strategies for drug clinical trials in China. China Pharmacy 23(21): 1931–1933.
go back to reference Zeng, L.F., J. Liu, J.K. Pan, et al. 2015. Intentional attitude analysis for adverse drug event reporting of principal investigators in clinical trials. Chinese Journal of New Drugs 24(10): 1150–1154. Zeng, L.F., J. Liu, J.K. Pan, et al. 2015. Intentional attitude analysis for adverse drug event reporting of principal investigators in clinical trials. Chinese Journal of New Drugs 24(10): 1150–1154.
go back to reference Zhou, Y.Z., Y.P. Zhang, T.T. Guo, et al. 2015. Reporting of informed consent and ethics committee approval in clinical trials of antihypertensive drugs. Chinese Journal of New Drugs 24(10): 1141–1144. Zhou, Y.Z., Y.P. Zhang, T.T. Guo, et al. 2015. Reporting of informed consent and ethics committee approval in clinical trials of antihypertensive drugs. Chinese Journal of New Drugs 24(10): 1141–1144.
Metadata
Title
An Exploration of the Protective Effects of Investigators’ Ethical Awareness upon Subjects of Drug Clinical Trials in China
Authors
L. Zhang
X. X. Huang
H. F. Chen
Publication date
01-03-2018
Publisher
Springer Singapore
Published in
Journal of Bioethical Inquiry / Issue 1/2018
Print ISSN: 1176-7529
Electronic ISSN: 1872-4353
DOI
https://doi.org/10.1007/s11673-017-9826-5

Other articles of this Issue 1/2018

Journal of Bioethical Inquiry 1/2018 Go to the issue